Violeta Serra
University of Pisa(IT)Hebron University(PS)European Commission(BE)Instituto de Salud Carlos III(ES)Centro de Investigación en Red en Enfermedades Cardiovasculares(ES)Vall d'Hebron Institut de Recerca(ES)Centro de Investigación Biomédica en Red(ES)Vall d'Hebron Hospital Universitari(ES)Joint Research Centre(DE)Joint Research Centre(NL)Vall d'Hebron Institute of Oncology(ES)Vall d'Hebron Institute of Oncology
Publications by Year
Research Areas
PARP inhibition in cancer therapy, Advanced Breast Cancer Therapies, BRCA gene mutations in cancer, Cancer Genomics and Diagnostics, DNA Repair Mechanisms
Most-Cited Works
- → AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity(2011)953 cited
- → NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations(2008)796 cited
- → Development of PI3K inhibitors: lessons learned from early clinical trials(2013)761 cited
- → Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer(2016)761 cited
- → A decade of clinical development of PARP inhibitors in perspective(2019)703 cited
- → Interrogating open issues in cancer precision medicine with patient-derived xenografts(2017)657 cited